Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast cream 0.15% bridging study in atopic dermatitis
NCT06631170Phase 3Completed
- Sponsor
- Huadong Medicine
- Start
- Nov 2024
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of roflumilast vehicle cream in atopic dermatitis (AD) (2 arms), sponsored by Huadong Medicine. Primary endpoint: Percentage of subjects with vIGA-AD success at 4 weeks. Started Nov 2024; status: completed.
02
Drugs
roflumilast vehicle cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06631170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631170.